

RoActemra® (tocilizumab) infusion dosing for Rheumatoid Arthritis (RA)

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to minimise important selected risks

RoActemra is available in three different dosing vials:

 400 mg (20 ml)  200 mg (10 ml)  80 mg (4 ml)

8 mg/kg

Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
50	110.0	400	20.0	
52	114.4	416	20.8	 +  +  + 
54	118.8	432	21.6	 +  +  + 
56	123.2	448	22.4	 + 
58	127.6	464	23.2	 + 
60	132.0	480	24.0	 + 
62	136.4	496	24.8	 +  +  +  + 
64	140.8	512	25.6	 +  +  +  + 
66	145.2	528	26.4	 +  + 
68	149.6	544	27.2	 +  + 
70	154.0	560	28.0	 +  + 
72	158.4	576	28.8	 + 
74	162.8	592	29.6	 + 
76	167.2	608	30.4	 +  +  + 
78	171.6	624	31.2	 +  +  + 
80	176.0	640	32.0	 +  +  + 
82	180.4	656	32.8	 +  + 
84	184.8	672	33.6	 +  + 
86	189.2	688	34.4	 +  +  +  + 
88	193.6	704	35.2	 +  +  +  + 
90	198.0	720	36.0	 +  +  +  + 
92	202.4	736	36.8	 +  +  + 
94	206.8	752	37.6	 +  +  + 
96	211.2	768	38.4	 + 
98	215.6	784	39.2	 + 
≥100	≥220.0	800	40.0	 + 

Dosing calculation: **Patient's weight (kg) x 8 = RoActemra dose (mg)**.
For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.

1. Calculate the appropriate dose

RoActemra infusion dosing is calculated based on the individual patient's weight. Verify the patient's weight and then locate it on the chart to find the corresponding dose and recommended vial combination.

If the dose has been previously calculated, check the patient's weight to make sure a dosage change is not needed. If there has been a significant change in weight, please consult the prescriber.

2. Choose the vial combination of RoActemra that best matches your patient's needs

RoActemra is available in three different dosing vials:

 400 mg (20 ml)  200 mg (10 ml)  80 mg (4 ml)

RoActemra is administered as a 60-minute, IV infusion at 4-week intervals.

Infusion reactions

During the infusion, watch the patient closely for any signs and symptoms of hypersensitivity, including anaphylaxis. If an anaphylactic reaction or other serious hypersensitivity/serious infusion related reaction occurs, administration of RoActemra should be stopped immediately and RoActemra should be permanently discontinued. Fatal anaphylaxis has been reported during treatment with RoActemra.

Full prescribing information can be found in the RoActemra Summary of Product Characteristics (SmPC) via the electronic Medicines Compendium (eMC) website: www.medicines.org.uk.

If you have any further questions relating to RoActemra please contact Roche Medical Information on +44(0)1707 361010 or email: medinfo.uk@roche.com.



Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

As RoActemra is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.